Immune Correlates of Denileukin Diftitox Treatment in TFH-Type Lymphoma
Background/Objectives: Follicular helper T-cell (TFH)-type lymphomas, including angioimmunoblastic T-cell lymphoma (AITL) and TFH lymphoma, not otherwise specified (TFH-NOS), are characterized by marked immune dysregulation in the tumor microenvironment. We investigated whether TFH-type lymphomas are enriched in immunosuppressive cells and explored immunologic changes associated with denileukin diftitox (DD) treatment. Methods: FOXP3-positive mononuclear cells were quantified by immunohistochemistry in lymph node specimens from 10 patients with TFH-type lymphoma and six with non-TFH-type T-cell lymphoma. Paired skin biopsy specimens obtained before and after DD treatment from two patients with AITL were evaluated for CD4, CD8, CD68, CD163, and FOXP3 expression. Longitudinal flow cytometric T-cell receptor Vβ repertoire analysis of CD8-positive T-cell subsets was performed in three patients with AITL treated with DD. Clinical responses were retrospectively assessed in seven patients with relapsed or refractory TFH-type lymphoma treated with DD. Results: TFH-type lymphomas showed significantly higher intra-tumoral FOXP3-positive cell densities than non-TFH-type lymphomas (p = 0.0024). In paired skin biopsies, DD treatment was associated with reductions in CD68- and CD163-positive macrophage-rich infiltrates and a suggested decrease in FOXP3-positive cells. Among seven patients treated with DD, the overall response rate was 86%, including one complete response and five partial responses. Responders showed selective Vβ over-representation patterns in effector and/or memory CD8-positive T-cell subsets, whereas such findings were not convincing in the non-responder. Conclusions: TFH-type lymphomas were associated with higher FOXP3-positive cell density than selected non-TFH-type comparators. DD treatment may be associated with changes in tissue immune infiltrates and peripheral CD8/TCR Vβ skewing in responding cases, although these findings remain exploratory and do not establish causality.
Authors
- Kazuto Shigematsu
- Kuniko Abe
- Ritsuko Kubota‐Koketsu (ORCID: https://orcid.org/0000-0002-0623-038X)
- Jun Taguchi (ORCID: https://orcid.org/0000-0003-2668-727X)
- Kazuhiro Noguchi (ORCID: https://orcid.org/0000-0002-4167-1594)
- Takahiro Sakai (ORCID: https://orcid.org/0000-0003-3382-9707)
- Kaori Yamaguchi
- Masatoshi Matsuo
- Kaho Umemoto
- Tatsuro Jo
- Yasushi Sawayama
Institutions
- Japanese Red Cross Society, Japan (JP)
- Nagasaki University Hospital (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- Cancers
- Published
- 2026-05-09
- DOI
- https://doi.org/10.3390/cancers18101529
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00